HomepageNBIX • NASDAQ
add
Neurocrine Biosciences
$Â 151,96
Na sluitingstijd:(0,00%)0,00
$Â 151,96
Gesloten: 3 dec, 17:20:00 GMT-5 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$Â 152,48
Dag-range
$Â 150,26 - $Â 154,35
Jaar-range
$Â 84,23 - $Â 157,67
Beurswaarde
15,15Â mld. USD
Gem. volume
1,08Â mln.
Koers/winst
36,28
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 794,90Â mln. | 27,78% |
Bedrijfskosten | 291,60Â mln. | 24,46% |
Netto inkomsten | 209,50Â mln. | 61,40% |
Netto winstmarge | 26,36 | 26,37% |
Winst per aandeel | 2,17 | 19,89% |
EBITDA | 247,00Â mln. | 29,12% |
Effectief belastingtarief | 28,20% | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 1,11Â mld. | -9,22% |
Totale activa | 4,27Â mld. | 20,67% |
Totale passiva | 1,26Â mld. | 54,65% |
Totaal aandelenvermogen | 3,00 mld. | — |
Uitstaande aandelen | 99,71 mln. | — |
Koers-boekwaardeverhouding | 5,06 | — |
Rendement op activa | 14,67% | — |
Rendement op kapitaal | 17,95% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 209,50Â mln. | 61,40% |
Operationele kasstroom | 227,50Â mln. | 43,99% |
Kasstroom uit beleggingen | -196,70Â mln. | -896,36% |
Kasstroom uit financiering | 45,60Â mln. | 72,73% |
Nettomutatie in liquide middelen | 76,20Â mln. | -63,61% |
Vrije kasstroom | -35,14Â mln. | -237,86% |
Over
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Opgericht
1992
Hoofdvestiging
Website
Werknemers
1.800
